Nektar Therapeutics

Nektar Therapeutics

Health CarePharmaceuticals & Biotechnology
  • Price (USD)31.68
  • Today's Change0.49 / 1.57%
  • Shares traded3.75m
  • 1 Year change-65.77%
  • Beta2.9932
Data delayed at least 15 minutes, as of Apr 18 2019 21:00 BST.
More ▼

Profile data is unavailable for this security.

About the company

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.

  • Revenue in USD (TTM)1.19bn
  • Net income in USD681.36m
  • Incorporated1998
  • Employees618.00
  • Location
    Nektar Therapeutics455 Mission Bay Blvd SSAN FRANCISCO 94158-2158United StatesUSA
  • Phone+1 (415) 482-5300
  • Fax+1 (302) 655-5049
  • Websitehttp://www.nektar.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Horizon Pharma PLC1.21bn-111.58m4.60bn1.00k--3.9927.973.81-0.688-0.46367.226.240.28936.582.781,207,570.00-2.67-6.58-3.29-7.8365.0361.62-9.24-22.751.960.08210.6428--14.3374.7976.59---33.32--
Tilray Inc43.13m-67.72m4.74bn313.00--23.08--109.90-1.02-1.020.5522.12----------------33.10---157.02--20.75-3.530.6847--110.00---767.24------
Syneos Health Inc4.39bn23.06m4.74bn24.00k223.791.6515.981.080.20430.215641.8227.630.6038--3.86182,921.500.31721.210.38831.560.340023.530.52521.65--2.750.49750.0064.3034.56152.44--25.25--
Array Biopharma Inc241.26m-111.47m4.89bn298.00--17.09--20.25-0.5279-0.52791.141.310.4769--9.24809,607.40-22.03-39.95-26.11-54.5885.5462.57-46.20-77.79---17.460.3174--15.1920.09-26.13---12.04--
Ascendis Pharma A/S11.88m-146.09m4.99bn216.00--14.44--419.90-3.58-3.580.28937.460.0399--109.0855,006.58-49.10-47.76-55.68-54.24-----1,229.53-940.49----0.00--591.57-12.31-5.00--17.25--
Alkermes Plc1.09bn-139.31m5.27bn2.30k--4.47--4.81-0.8994-0.89947.057.520.60421.924.10475,771.30-7.69-8.24-9.31-9.3783.8880.50-12.73-18.582.63-15.990.1926--21.13---2.07------
Nektar Therapeutics1.19bn681.36m5.52bn618.008.772.947.974.623.613.616.9310.770.89762.2149.491,930,943.0051.2516.4454.0618.3497.9592.9557.1025.9417.3916.080.1257--287.8151.62349.85--28.33--
Amarin Corporation plc (ADR)229.22m-116.45m5.95bn530.00--45.10--25.95-0.3909-0.39090.77120.46750.83761.244.10432,481.10-42.55-43.83-82.73-70.2776.2073.06-50.80-64.292.04-13.880.3453--26.5654.13-92.58--32.88--
Guardant Health Inc-100.00bn-100.00bn6.06bn454.00--12.53----------5.63------------------------9.80--0.0004--81.85--4.42------
PRA Health Sciences Inc2.87bn156.81m6.19bn16.40k39.975.9122.972.162.362.3243.3015.980.8777--4.81175,117.204.802.936.743.9227.9029.055.473.74--5.430.50730.0027.1123.7156.71--23.17--
Exelixis, Inc.853.83m690.07m6.30bn484.009.454.879.037.382.212.212.734.290.82193.197.111,764,103.0066.4312.2374.3216.2196.9196.5480.8222.508.41--0.00010.0088.7093.67347.44--72.64--
Catalent Inc2.49bn132.90m6.40bn10.70k45.794.1018.582.570.96030.985517.8010.730.56367.295.08232,523.403.013.483.394.0231.1531.945.345.731.612.830.58460.0018.706.4714.94--7.58--
Charles River Laboratories Intl. Inc2.27bn219.37m6.59bn14.70k30.174.9517.182.914.484.6246.2727.330.667911.745.02154,156.206.537.017.758.3937.0737.809.7810.201.385.690.55480.0021.9914.228.6016.0829.03--
Perrigo Company PLC4.73bn130.90m6.63bn10.60k52.001.1711.961.400.93880.938834.1841.710.41853.444.29446,386.801.16--1.33--38.71--2.77--1.324.280.3639---4.34---2.75------
Data as of Apr 18 2019. Currency figures normalised to Nektar Therapeutics's reporting currency: US Dollar USD

Institutional shareholders

65.88%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co.as of 31 Dec 201825.25m14.50%
PRIMECAP Management Co.as of 31 Dec 201819.40m11.14%
The Vanguard Group, Inc.as of 31 Dec 201818.07m10.38%
OppenheimerFunds, Inc.as of 31 Dec 201817.30m9.94%
Wellington Management Co. LLPas of 31 Dec 201810.74m6.17%
BlackRock Fund Advisorsas of 31 Dec 201810.07m5.79%
SSgA Funds Management, Inc.as of 31 Dec 20186.79m3.90%
Henderson Global Investors Ltd.as of 31 Dec 20182.53m1.45%
First Trust Advisors LPas of 31 Dec 20182.31m1.33%
Geode Capital Management LLCas of 31 Dec 20182.23m1.28%
More ▼
Data from 31 Dec 2018 - 31 Dec 2018Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.